Roy, Pushpita, et al. “Magnitude of Survival Benefit Associated With Tyrosine Kinase Inhibitors in Advanced Thyroid Carcinoma: A Systematic Review and Meta-Analysis Incorporating Updated Long-Term Evidence From SELECT (Lenvatinib) and COSMIC-311 (Cabozantinib) Trials”. World Journal of Oncology, vol. 17, no. 5, Jan. 2026, pp. 599-13, https://doi.org/10.14740/wjon2842.